The report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. The therapy class report highlights the future potential of this stream of medicine and the radical way diseases could be treated in the next few decades. This new stream of medicine is driven by landmark scientific discoveries and research (Nobel prize in 2012). In recent years the translation of research into the clinic has been spearheaded by Rising stars companies (RS). Some of them have come in the limelight because of their technology platform, clinical data, successful IPO etc. We expect most of these home grown technologies/products developed by the RS/ Research collaborations to fuel the pipeline of the large pharma through acquisition or collaboration when the drug is in late stage or approved. The Regenerative medicine Universe is large and new companies are being added to it rapidly. As a result we have used some filters to select a few names for a detailed coverage in our Outlook this year. Needless to say that this could just be the tip of the iceberg!

1. THERAPEUTIC CLASS OVERVIEW
Therapeutic Class Overview : Regenerative Medicines
RegnerativeMedicines
REGENERATIVE MEDECINE
RegnerativeMedicines

2. Table of Contents
Therapeutic Class Overview : Regenerative Medicines
Regenerative Medicines /01
RegnerativeMedicines
Regenerative Medicine and Stem cell based Cell therapies-
Drugs of the Future Offering Hope for Cure
• EXECUTIVE SUMMARY
• INTRODUCTION
• Tough Choice- “Autologous vs. Allogenic " Therapies
• REGULATORY GUIDELINES
• Marketed Cell based/Stem Cell Products
• Progress and Challenges
• Progress in Specific Therapy Areas
• SELECT UPCOMING MILESTONES IN REGENERATIVE MEDICINE/STEM
CELL FOCUSED COMPANIES (2015-16)
• Appendix
• Merger and Acquisition- Gaining Momentum in Regenerative Space
– Dawn of the Golden Era for Regenerative Medicine/Stem cell based therapies
– Stem cells Types
– Mesenchymal stem cells (MSCs)
– Japan and Asia Lead the Way
– Japanese Adaptive Licensing Legislation
– South Korea Regulatory Update
– India Regulatory Update
– Regulatory Scenario in US and EU
– Diabetes
– Cardiovascular Disease
– Musculoskeletal (MSD) Related Conditions
– Ocular Disease
– Approved Cell-based / Stem Cell Therapies in Korea and WW
– Cost of Treatment of Approved Therapies
– Reimbursement of Approved Cell based Therapies!
Table Of Contents : Regenerative Medicines /01